GE HEALTHCARE TECHNOLOGY
GEHCNASDAQTrading Snapshot
- Day Range
- $65.79 β $67.27
- 52-Week Range
- $58.75 β $89.77
- Volume
- $2.54B
- Avg Volume
- $3.35B
- Shares Outstanding
- 451.7M
- Next Earnings
- Oct 26, 2026
Fundamentals Snapshot
- Annual Revenue
- $20.63B
- Last Q Revenue
- $5.29B
- P/E Ratio
- 15.2
- P/S Ratio
- 1.4x
- EPS (TTM)
- $4.35
- Dividend Yield
- 0.21%
- Dilution (1yr)
- +0.3%
Why Investors Own GEHC
- βHigh-growth profile β revenue up -6.4% YoY with expanding US Equity exposure.
- βHealthy economics β 62% gross margin and 18% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
GE HEALTHCARE TECHNOLOGY
GEHCAbout GE HEALTHCARE TECHNOLOGY
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals β molecular tracers labeled with radioisotopes β injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates
Here's Why You Should Add GEHC Stock to Your Portfolio Right Now
GEHC's record backlog, strong orders and AI-enabled innovations offer growth potential, while inflation and China remain key risks.

GE HealthCare announces cash dividend increase for third quarter of 2026
CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.04 per share of Common Stock for the third quarter of 2026, an increase of 14% from

GE HealthCare appoints veteran finance executive Pascal Desroches to Board of Directors
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced the appointment of Pascal Desroches, Senior Executive Vice President and Chief Financial Officer (CFO) of AT&T (NYSE: T), a Fortune 50 company, to it

Securities Fraud Investigation Into GE HealthCare Technologies Inc. (GEHC) Continues β Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
LOS ANGELES, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of GE HealthCare Technologies Inc. (βGE HealthCareβ

GE HealthCare Technologies Inc. (GEHC) Shareholders Who Lost Money β Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
BENSALEM, Pa., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G.

Securities Fraud Investigation Into GE HealthCare Technologies Inc. (GEHC) Continues β Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
LOS ANGELES, Sept. 16, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of of GE HealthCare Technologies Inc. (βGE HealthCareβ or the βCompanyβ) (NASDAQ: GEHC) on behalf of investors